UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Incannex announces positive topline results from phase 2 Psi-GAD1 clinical trial of psilocybin in generalised anxiety disorder
This is the first time psilocybin has been investigated for treatment of generalised anxiety disorder, and the reduction in HAM-A scores we have observed are far greater those reported from trials on established medicines for treatment of anxiety.
MindMed announces positive 12-week data from phase 2B study of MM120 for GAD
FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD)."